KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) FCF Margin: 2019-2025

Historic FCF Margin for Royalty Pharma (RPRX) over the last 6 years, with Sep 2025 value amounting to -42.55%.

  • Royalty Pharma's FCF Margin rose 4439.00% to -42.55% in Q3 2025 from the same period last year, while for Sep 2025 it was 40.20%, marking a year-over-year increase of 4958.00%. This contributed to the annual value of 11.63% for FY2024, which is 2542.00% down from last year.
  • Royalty Pharma's FCF Margin amounted to -42.55% in Q3 2025, which was down 167.86% from 62.71% recorded in Q2 2025.
  • Over the past 5 years, Royalty Pharma's FCF Margin peaked at 104.71% during Q1 2025, and registered a low of -147.88% during Q3 2021.
  • Its 3-year average for FCF Margin is 28.85%, with a median of 41.46% in 2024.
  • Per our database at Business Quant, Royalty Pharma's FCF Margin surged by 15,840bps in 2023 and then crashed by 11,481bps in 2024.
  • Quarterly analysis of 5 years shows Royalty Pharma's FCF Margin stood at 55.28% in 2021, then surged by 123bps to 56.51% in 2022, then plummeted by 9,503bps to -38.52% in 2023, then skyrocketed by 7,998bps to 41.46% in 2024, then skyrocketed by 4,439bps to -42.55% in 2025.
  • Its last three reported values are -42.55% in Q3 2025, 62.71% for Q2 2025, and 104.71% during Q1 2025.